Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Item

http://www.wikidata.org/entity/Q33447149

Q33447149

about

Targeted therapies in sarcomas: challenging the challenge Pazopanib in the management of advanced soft tissue sarcomas Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review Pazopanib in sarcomas: expanding the PALETTE Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Anti-angiogenic gene therapy in the treatment of malignant gliomas Receptor tyrosine kinase-mediated angiogenesis Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis TP53 mutational status is predictive of pazopanib response in advanced sarcomas.Update on clinical research and state of the art management of patients with advanced sarcomas and GIST Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas Treatment of Adult Soft Tissue Sarcomas: An Overview Pazopanib in the treatment of soft tissue sarcoma Pazopanib, a new therapy for metastatic soft tissue sarcoma Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models Advances and controversies in the management of soft tissue sarcomas.A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).The evolution of systemic therapy in sarcoma.Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma.Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide.

P2860

Q21285014-8DE2CD92-1CD6-421B-9BB4-42B32321F715 Q26746205-15C7E0D5-4CD2-44A3-B450-3B28708F7A41 Q26747666-65C4ED0F-63E0-4D4D-AB59-D36FB847BD11 Q26822530-9D731C1C-3C3E-4F4D-98DA-B6ED8682D0E5 Q26825050-B29C9E34-6852-4820-85F6-8D8B5A4F3596 Q26851417-567FE157-045B-443A-813E-FF95315CC113 Q26866276-42FF8C3E-1C2F-4C59-A201-B1877FF07D78 Q27001612-34C185D7-95E6-4754-A789-E91D12188F1F Q27026453-06DC7C7B-0170-4257-9CAB-8A3CE0163BB9 Q27853289-54746885-6F09-4D0D-86E2-47C130ACEEE4 Q28073290-08122C17-812A-47D3-BA63-AFB54CA1EDCC Q28076041-FC978C9C-7271-49DA-9452-67A3B86C7616 Q28076210-2F3A6DDC-52DA-498F-B197-A66F4F5A0184 Q28088685-2CF14169-F350-428C-B3F0-1C141172067A Q28269229-71D81434-E47E-4B42-93C8-5226BF63D431 Q28287163-C292DF79-8A80-4DE9-81CC-AC5955927246 Q28485467-93496C4F-2BD7-4B77-8042-B00685BAEB32 Q28744228-B62213A0-75A5-4178-80D0-4917F4CE91C4 Q30240228-A8B32D1A-DEA2-4A34-B1E9-258AF97E6E74 Q30370631-6D6C057C-D929-44DF-B6DA-21565B101C79 Q30585642-EE445FF4-C52A-499B-A601-CC770DCFDB58 Q31010355-1277163F-9366-484D-943B-2DFC5E45C13D Q31018689-BC503706-9DE0-4CF1-BB5F-FB32725818EB Q33274710-01A38863-61D3-4ED2-982A-DC8A8DAF893A Q33276109-F07A36E3-78A1-4E80-9093-A0F82CE7988D Q33388438-1F188A7C-80FE-48AD-967A-BEBD5AC1AC53 Q33395853-58120E50-49F0-4A89-846F-4D23EE629809 Q33406371-2F91B616-1ED6-4DDE-B425-806D78CDADBE Q33407600-110FEAF7-D015-4D61-BA5D-FDDFA5849651 Q33408668-BC235159-DF3D-460A-9805-16F1B2E24054 Q33430673-12BCE718-73E8-4751-A7E3-375C7DA13F03 Q33433105-93DC71DE-67B0-4DDF-B91A-C341EAF30CA0 Q33590458-95F14D2D-37B2-4D00-924B-9B80E75D3D60 Q33633424-59C7309E-0862-4372-9026-73D7A6DF9176 Q33686273-D4DA5846-3A93-4A7F-89C7-DD80AB82D721 Q33780689-4A1D526D-5133-4B25-A78F-3CE25FA46185 Q33780751-E849C351-493A-423D-A1D4-9CD0C33459C0 Q33834417-3F642D17-7E4C-4526-8B6F-37588F00C9C3 Q33859472-5C503FD9-4F0A-4525-B740-AAC9F2FBFB1D Q33869797-5636CEF6-A421-4E80-B467-BF37FE54FAC2

P2860

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Item

http://www.wikidata.org/entity/Q33447149

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu